Wissenschaftl. Titel | International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in Hormone Receptor-positive/HER2-negative advanced breast cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment |
Erkrankung |
Gyn:
Mamma-Ca:
Zweitlinie oder später
|
Kurzprotokoll | Kurzprotokoll |
Links | Weiterführende Informationen (M) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 30.11.2020 Data entry XI CCP
geändert 28.01.2021 Data entry IX CCP